Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Crohn's Disease
88%
Inflammatory Bowel Disease
60%
Pediatric Inflammatory Bowel Disease
51%
Pediatric Patients
44%
Tumor Necrosis Factor-α
33%
Pediatric Crohn's Disease
32%
Ulcerative Colitis
29%
Infliximab
28%
Pediatric
25%
Granulocyte Colony-stimulating Factor (G-CSF)
21%
Hepatocytes
21%
Hepatocyte Apoptosis
19%
Treatment Failure
18%
95% Confidence Interval
16%
Nuclear factor-κB
15%
Adalimumab
14%
Apoptosis
13%
Monotherapy
12%
Combination Therapy
12%
Corticosteroids
12%
Budesonide
12%
Remission
12%
Delayed Diagnosis
11%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
11%
Hepatocyte Proliferation
11%
NOD2
10%
Ileitis
10%
Anti-drug Antibodies
10%
Granulocyte-macrophage Colony-stimulating Factor Autoantibodies
10%
Apoptosis Induction
10%
Odds Ratio
10%
Gene-deficient Mice
9%
Pragmatic Trial
9%
Protein Expression
9%
Antibody Development
9%
Improved Outcomes
9%
Methotrexate
9%
Anti-tumor Necrosis Factor Therapy
9%
Pragmatic Clinical Trial
9%
Ileal Crohn's Disease
8%
Obstructive Jaundice
8%
Low-dose Methotrexate
8%
Statural Growth
8%
Expected Growth
8%
Growth Plate Closure
8%
Comparative Effectiveness
8%
Non-alcoholic Fatty Liver Disease (NAFLD)
8%
Learning Health System
8%
Monogenic
8%
Juvenile Idiopathic Arthritis
8%
Medicine and Dentistry
Pediatrics
100%
Inflammatory Bowel Disease
67%
Crohn's Disease
56%
Pediatrics Patient
42%
Patient with Crohn's Disease
25%
Biological Product
25%
Hepatocyte
24%
Ulcerative Colitis
23%
Infliximab
20%
Tumor Necrosis Factor
19%
Programmed Cell Death
17%
Quality Improvement
16%
Patient with Inflammatory Bowel Disease
15%
Therapeutic Drug Monitoring
12%
Odds Ratio
10%
Patient-Reported Outcome
10%
Adolescence
10%
Health System
10%
Monotherapy
9%
Methotrexate
8%
Necrosis
8%
Electronic Health Record
8%
Nonalcoholic Fatty Liver
8%
Outcome Assessment
8%
Clinical Trial
8%
Epiphyseal Plate
8%
Juvenile Idiopathic Arthritis
8%
Budesonide
8%
Emergency Department
8%
Closed Head Injury
8%
Computer Assisted Tomography
8%
Cell Cycle
8%
Mating Hormone Alpha Factor
8%
Gut
8%
Infusion
8%
Protein Binding
8%
Histoplasmosis
8%
Immunosuppressant
8%
Case-Control Study
8%
Diagnostic Delay
8%
Inflammation
8%
Mercaptopurine
8%
Adalimumab
8%
Reactive Oxygen Species
8%
Smad Protein
8%
Low Drug Dose
8%
Growth Inhibition
8%
Protein Expression
8%
Medical Record
7%
Immunoglobulin Enhancer Binding Protein
6%
